Drugs / RGX-314
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03066258 | Mar 2017 → Nov 2019 | wet macular degeneration | REGENXBIO Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06942520 | Mar 2025 → Dec 2027 expected | diabetic macular edema | Sierra Eye Associates | Recruiting | No outcome recorded |
| Phase 2 | NCT04832724 | Feb 2021 → Oct 2023 | wet macular degeneration | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03999801 | May 2019 → Dec 2028 expected | wet macular degeneration | AbbVie | Enrolling by invitation | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-13 | AbbVie | AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program abbvie.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGX-314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04832724 ↗ |
| Known as | ABBV-RGX-314 | “RGX-314 (currently known as ABBV-RGX-314) is an adeno-associated virus serotype 8 vector” PMID 38554726 ↗ Mar 2024 |
| Action | Inhibit | “RGX-314 gene therapy provides a novel approach for sustained VEGF-A suppression in patients with nAMD” PMID 38554726 ↗ Mar 2024 |
| Modality | Gene therapy (AAV / viral vector) | “RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector” NCT03066258 ↗ |
| Route | Other | “subretinal administration” NCT03999801 ↗ |
| Target | VEGFA | “RGX-314 (currently known as ABBV-RGX-314) is an adeno-associated virus serotype 8 vector that expresses an anti-VEGF-A antigen-binding fragment, which provides potential for...” PMID 38554726 ↗ Mar 2024 |